The Data Supporting Dolutegravir and DTG/3TC in Children Living With HIV
The dolutegravir application drew on IMPAACT 2023, a study sponsored by the Division of AIDS and funded by the National Institutes of Health.¹ Pharmacokinetic modeling incorporating additional pediatric data showed dolutegravir reaches therapeutic drug levels in term neonates.¹ No new safety findings emerged compared with older pediatric populations.¹
The DTG/3TC application relied on Penta-21, a pediatric and adult pharmacokinetic study sponsored by the PENTA Foundation, along with the DANCE study.¹ Regulators evaluated these data alongside extrapolated results from the adult GEMINI and TANGO trials, which support a favorable benefit/risk profile in treatment-naive and virologically suppressed pediatric populations.¹ Safety and tolerability for both agents were consistent with known profiles in older pediatric and adult patients; the announcement did not report hepatotoxicity signals or resistance emergence.¹
What You Need to Know
If adopted, the CHMP opinion would make dolutegravir the first second-generation INSTI in the EU for eligible term newborns weighing at least 2 kg, building on the FDA’s August 2026 approval of Tivicay PD for the same group.
A new dolutegravir/lamivudine dispersible tablet would give children at least 3 months old who weigh 6 kg to less than 25 kg their first single-tablet, two-drug regimen in the EU, as long as they have no known INSTI or lamivudine resistance.
Recent adult data back the pediatric expansion: dolutegravir/lamivudine was noninferior to bictegravir/emtricitabine/tenofovir alafenamide in the VOGUE trial, and updated HHS guidelines now recommend it regardless of baseline viral load.
The adult evidence base for DTG/3TC continued to grow this year. The phase 3b VOGUE trial, presented at AIDS 2026, randomized 509 treatment-naive adults to DTG/3TC or bictegravir/emtricitabine/tenofovir alafenamide.³ At week 48, 89% vs 92% achieved HIV-1 RNA below 50 copies/mL (adjusted difference, −3 percentage points; 95% CI, −8 to 2), meeting noninferiority.³ No treatment-emergent resistance occurred in either arm.³
Updated September 2026 US Department of Health and Human Services adult and adolescent guidelines now recommend DTG/3TC regardless of baseline plasma HIV viral load, based on the DOLCE study.⁴ The panel advises against DTG/3TC as a switch strategy for people with historical M184V/I mutations.⁴
“Children living with HIV require lifelong care, making continued innovation essential,” Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, said in the announcement.¹ “These positive CHMP opinions mark an important step towards expanding age-appropriate, INSTI-based treatment options for children and advancing our goal of offering greater choice in HIV care.”¹
If the European Commission adopts both opinions, clinicians in the EU would gain INSTI-based options spanning birth through adolescence, including a single-tablet, two-drug regimen for children as light as 6 kg.¹ The pending FDA decision on pediatric DTG/3TC could bring a similar option to younger children in the US.¹
References
ViiV Healthcare’s Tivicay and Dovato receive positive CHMP opinion for young children living with HIV, advancing efforts to close paediatric treatment gaps in the EU. News release. ViiV Healthcare; November 16, 2026.